Lighting up the path to a better neural future to improve peoples’ lives.

We’re inventing breakthrough neuroelectronic therapies to help mankind solve the neural challenge.

%

of world population is affected by neural disorders
— Prev Med Rep. 2018 Dec & Lancet Neurol 2019

They are the leading cause of disability and the 2nd cause of mortality worldwide.
— World Health Organization, 2022

Incurring an annual cost for society exceeding cost of cancer and cardiovascular diseases combined.
— World Health Organization, 2022

Current neuroelectronic therapies are invasive, low-resolution and generic.

Recharging patients' lives

Our end-to-end neural platform combines hardware and data analytics to decode & modulate neural networks, maximize time on therapy and effectively restore function or mobility for patients.

  • Icône

    Skin-like, bi-directional, high resolution (up to 1024 contacts) brain-computer interfaces (BCI) enabling real-time smart neural decoding and modulation in closed loop.

  • Icône

    Implantable compact neural processor with wireless rechargeable battery, powering signal processing.

  • Icône

    AI-powered platform empowering patients and clinicians to harness their own data through therapy personalization, focusing on improving the outcomes that matter to patients.

  • Icône

    Our platform has received FDA Breakthrough Device Designation for use in Parkinson’s Disease.

A spark of genius

Harnessing the potential of Graphene, we power up science and technology to decode the brain and revolutionize neural disorders treatment.

We’re on a mission to decode and modulate the brain, but also the entire neural system.

[NEWS] We just received FDA Breakthrough Device Designation [NEWS] We just received FDA Breakthrough Device Designation [NEWS] We just received FDA Breakthrough Device Designation [NEWS] We just received FDA Breakthrough Device Designation

A team of live wires

We are a team of highly experienced materials and neurotech believers, backed by leading tech and scientific advisors.

Latest news

Follow our story